Another RICOdiculous Decision
Drug & Device Law
JULY 24, 2023
341 (2001). Yet what the plaintiffs were claiming is that, despite Actos’ undisputed effectiveness as a diabetes treatment, no TPP in the country would have purchased it for that purpose because of the 3/10,000 bladder cancer increased risk. the relationship between [plaintiff] and its pharmacy benefit manager. . . 3d at 1251.
52 
Let's personalize your content